{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:52:11Z","timestamp":1792803131802,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jacc.2025.11.028","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:18:09Z","timestamp":1772551089000},"page":"1063-1083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"87","author":[{"given":"Louise","family":"Bjerregaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Dybro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Saaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten Bloch","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Steen Kvistholm","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jacc.2025.11.028_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2025.11.028_bib2","first-page":"53","article-title":"Hypertrophic cardiomyopathy: a review","volume":"8","author":"Houston","year":"2014","journal-title":"Clin Med Insights Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"10.1016\/j.jacc.2025.11.028_bib4","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.jacc.2025.11.028_bib5","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Writing Committee Members","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/0002-9149(83)90317-X","article-title":"Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil","volume":"51","author":"Bonow","year":"1983","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2025.11.028_bib7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/01.CIR.68.5.1062","article-title":"Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe","volume":"68","author":"Bonow","year":"1983","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/01.CIR.72.4.853","article-title":"Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects","volume":"72","author":"Bonow","year":"1985","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacc.2025.11.028_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.CIR.35.5.847","article-title":"Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade","volume":"35","author":"Cohen","year":"1967","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacc.2025.11.028_bib10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.38.5.846","article-title":"Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol","volume":"38","author":"Flamm","year":"1968","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/hrt.32.6.804","article-title":"Long-term propranolol therapy in muscular subaortic stenosis","volume":"32","author":"Adelman","year":"1970","journal-title":"Br Heart J"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0002-9149(73)90012-X","article-title":"Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy","volume":"31","author":"Stenson","year":"1973","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/S0735-1097(99)00421-0","article-title":"A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment","volume":"34","author":"Ostman-Smith","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.028_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jama.287.10.1308","article-title":"Hypertrophic cardiomyopathy: a systematic review","volume":"287","author":"Maron","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib15","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1161\/01.CIR.60.6.1201","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.CIR.64.4.787","article-title":"Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertropihc cardiomyopathy","volume":"64","author":"Bonow","year":"1981","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jacc.2025.11.028_bib17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0002-9149(88)90268-8","article-title":"Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration","volume":"62","author":"Pollick","year":"1988","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2025.11.028_bib18","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0002-9149(94)90404-9","article-title":"Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy","volume":"74","author":"Gistri","year":"1994","journal-title":"Am J Cardiol"},{"issue":"10253","key":"10.1016\/j.jacc.2025.11.028_bib20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.jacc.2025.11.028_bib21","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.11.028_bib22","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.91.2.580","article-title":"Exercise standards. A statement for healthcare professionals from the American Heart Association","volume":"91","author":"Fletcher","year":"1995","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacc.2025.11.028_bib23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/01.CIR.57.3.549","article-title":"The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris","volume":"57","author":"Gobel","year":"1978","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1152\/jappl.1972.32.4.516","article-title":"Hemodynamic correlates of myocardial oxygen consumption during upright exercise","volume":"32","author":"Kitamura","year":"1972","journal-title":"J Appl Physiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.50.6.1179","article-title":"Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise","volume":"50","author":"Nelson","year":"1974","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2025.11.028_bib26","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1513\/AnnalsATS.201612-997FR","article-title":"Cardiopulmonary exercise testing: basics of methodology and measurements","volume":"14","author":"Mezzani","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.jacc.2025.11.028_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3949\/ccjm.84a.15013","article-title":"Cardiopulmonary exercise testing: a contemporary and versatile clinical tool","volume":"84","author":"Leclerc","year":"2017","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"10.1016\/j.jacc.2025.11.028_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmg.2018.10.038","article-title":"Left ventricular diastolic function. understanding pathophysiology, diagnosis, and prognosis with echocardiography","volume":"13","author":"Nagueh","year":"2020","journal-title":"JACC Cardiovasc imaging"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004814","article-title":"How does morphology impact on diastolic function in hypertrophic cardiomyopathy? A single centre experience","volume":"4","author":"Finocchiaro","year":"2014","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1540-8175.2008.00871.x","article-title":"Impaired myocardial function in hypertrophic cardiomyopathy","volume":"26","author":"Saccheri","year":"2009","journal-title":"Echocardiography"},{"issue":"11","key":"10.1016\/j.jacc.2025.11.028_bib32","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.amjcard.2016.03.018","article-title":"Relation of Doppler tissue imaging parameters with heart failure progression in hypertrophic cardiomyopathy","volume":"117","author":"Kalra","year":"2016","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib33","doi-asserted-by":"crossref","first-page":"iii9","DOI":"10.1093\/ejechocard\/jep157","article-title":"Echocardiography in hypertrophic cardiomyopathy diagnosis, prognosis, and role in management","volume":"10","author":"Williams","year":"2009","journal-title":"Eur J Echocardiogr"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib34","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.echo.2009.05.003","article-title":"The relationship of left atrial volume and left atrial pressure in patients with hypertrophic cardiomyopathy: an echocardiographic and cardiac catheterization study","volume":"22","author":"Geske","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"issue":"10","key":"10.1016\/j.jacc.2025.11.028_bib35","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.amjcard.2012.01.363","article-title":"Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"109","author":"Sorajja","year":"2012","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib36","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"21","key":"10.1016\/j.jacc.2025.11.028_bib37","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.028_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2022.10.009","article-title":"Betablockers reduce oxygen pulse increase and performance in heart failure patients with preserved ejection fraction","volume":"370","author":"Wernhart","year":"2023","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ehf2.12281","article-title":"Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction","volume":"5","author":"Dominguez","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.11.028_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jjcc.2023.06.014","article-title":"Characterization and prognostic importance of chronotropic incompetence in heart failure with preserved ejection fraction","volume":"83","author":"Yuasa","year":"2024","journal-title":"J Cardiol"},{"issue":"18","key":"10.1016\/j.jacc.2025.11.028_bib41","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1177\/2047487317739079","article-title":"Cardiopulmonary exercise testing as prognostic indicators: comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction","volume":"24","author":"Sato","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.11.028_bib42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCHEARTFAILURE.114.001825","article-title":"Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction","volume":"8","author":"Dhakal","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jchf.2016.03.022","article-title":"Cardiopulmonary exercise testing in heart failure","volume":"4","author":"Malhotra","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"13","key":"10.1016\/j.jacc.2025.11.028_bib44","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jacc.2017.08.012","article-title":"Cardiopulmonary exercise testing: what is its value?","volume":"70","author":"Guazzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2025.11.028_bib45","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1253\/circj.CJ-16-0432","article-title":"Heart failure progression in hypertrophic cardiomyopathy\u2014possible insights from cardiopulmonary exercise testing","volume":"80","author":"Magri","year":"2016","journal-title":"Circ J"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/heartjnl-2015-308453","article-title":"Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy","volume":"102","author":"Magri","year":"2016","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/CIRCHEARTFAILURE.108.785501","article-title":"Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone","volume":"1","author":"Lewis","year":"2008","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.11.028_bib48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/CIRCULATIONAHA.124.070064","article-title":"Exercise training in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction: a randomized clinical trial","volume":"151","author":"Gudmundsdottir","year":"2025","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacc.2025.11.028_bib49","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1249\/MSS.0000000000000605","article-title":"Resistance exercise training alters mitochondrial function in human skeletal muscle","volume":"47","author":"Porter","year":"2015","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"10.1016\/j.jacc.2025.11.028_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1113\/EP085319","article-title":"Adaptations of skeletal muscle mitochondria to exercise training","volume":"101","author":"Lundby","year":"2016","journal-title":"Exp Physiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.11.028_bib51","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0305-0491(87)90113-1","article-title":"Predictable adaptations by skeletal muscle mitochondria to different exercise training workloads","volume":"88","author":"Martin","year":"1987","journal-title":"Comp Biochem Physiol B"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib52","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/0002-9149(80)90487-7","article-title":"Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy","volume":"45","author":"Hanrath","year":"1980","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100622","article-title":"Medical therapies to improve left ventricular outflow obstruction and diastolic function in hypertrophic cardiomyopathy","volume":"2","author":"Zhu","year":"2023","journal-title":"JACC Adv"},{"issue":"3","key":"10.1016\/j.jacc.2025.11.028_bib54","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCULATIONAHA.107.694158","article-title":"Management of symptoms in hypertrophic cardiomyopathy","volume":"117","author":"Fifer","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib55","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1388-9842(01)00146-5","article-title":"Effect of metoprolol CR\/XL on exercise tolerance in chronic heart failure\u2014a substudy to the MERIT-HF trial","volume":"3","author":"Gullestad","year":"2001","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.jacc.2025.11.028_bib56","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/eurheartj\/ehaa587","article-title":"Assessing left ventricular systolic function: from ejection fraction to strain analysis","volume":"42","author":"Halliday","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2025.11.028_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ejhf.971","article-title":"Noninvasive assessment of left ventricular filling pressure","volume":"20","author":"Nagueh","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.jacc.2025.11.028_bib58","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.ahj.2009.06.006","article-title":"Mechanisms of exercise intolerance in patients with hypertrophic cardiomyopathy","volume":"158","author":"Le","year":"2009","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib59","first-page":"e86","article-title":"Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure","volume":"15","author":"Rehsia","year":"2010","journal-title":"Exp Clin Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2025.11.028_bib60","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","article-title":"Calcium channel blockers","volume":"13","author":"Elliott","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jacc.2025.11.028_bib61","series-title":"Selective beta-1 blockers","author":"Tucker","year":"2025"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib62","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40265-022-01728-w","article-title":"Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside","volume":"82","author":"Palandri","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jacc.2025.11.028_bib63","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacc.2025.11.028_bib64","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2025.11.028_bib65","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11886-021-01511-5","article-title":"Patient-reported outcomes in patients with cardiomyopathy","volume":"23","author":"Garcia","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib66","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.jacc.2025.11.028_bib67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ahj.2011.09.027","article-title":"Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure","volume":"163","author":"Flynn","year":"2012","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.jacc.2025.11.028_bib68","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib69","first-page":"539","article-title":"Switching between \u03b2-blockers: an empiric tool for the cardiovascular practitioner","volume":"35","author":"Roston","year":"2019","journal-title":"Can J Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.11.028_bib72","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"issue":"8","key":"10.1016\/j.jacc.2025.11.028_bib73","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","article-title":"Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy","volume":"3","author":"Hartman","year":"2024","journal-title":"Nat Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.jacc.2025.11.028_bib74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.11.028_bib75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.tcm.2014.09.004","article-title":"The 20 advances that have defined contemporary hypertrophic cardiomyopathy","volume":"25","author":"Maron","year":"2015","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jacc.2025.11.028_bib76","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.11.028_bib77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s43044-024-00600-4","article-title":"Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies","volume":"77","author":"Olalekan","year":"2025","journal-title":"Egypt Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2025.11.028_bib78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jchf.2023.10.004","article-title":"Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design","volume":"12","author":"Coats","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"21","key":"10.1016\/j.jacc.2025.11.028_bib79","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacc.2025.11.028_bib80","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","article-title":"Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"issue":"10","key":"10.1016\/j.jacc.2025.11.028_bib81","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa2505927","article-title":"Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy","volume":"393","author":"Desai","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jacc.2025.11.028_bib82","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725103331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725103331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:24:44Z","timestamp":1781511884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725103331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0735109725103331"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.11.028","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}